Supplementary Figure 13 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Authors:
- Matthew R. LevengoodMLMatthew R. Levengood
- Christopher M. CarosinoCCChristopher M. Carosino
- Xinqun ZhangXZXinqun Zhang
- Sasha LucasSLSasha Lucas
- David J. OrtizDODavid J. Ortiz
- Lori WestendorfLWLori Westendorf
- Alice P. ChinACAlice P. Chin
- Arlan D. MartinAMArlan D. Martin
- Abbie WongAWAbbie Wong
- Shawna M. HengelSHShawna M. Hengel
- Hao SunHSHao Sun
- Weiping ZengWZWeiping Zeng
Open Access
- 17 June 2026
- other
- Published by American Association for Cancer Research (AACR)